RESUMO
A 4-bp deletion in the ATP-binding cassette subfamily B member 1 (ABCB1) gene, also referred to as the multidrug resistance gene (MDR1), produces stop codons that cause premature termination of P-glycoprotein 1 (P-gp) synthesis. Dogs with the homozygous mutation do not express functional P-gp, which increases their sensitivity markedly to many common veterinary drugs. We detected the nt230 (del4) ABCB1 mutation in Border Collie dogs in western Mexico with a simple and affordable primer-introduced restriction analysis PCR (PIRA-PCR). PIRA-PCR clearly identified all genotypes in our sample of 104 dogs. Genotype frequencies were 0.952 (wild/wild), 0.029 (wild/mut) and 0.019 (mut/mut). Allele frequencies were 0.033 (mutant alleles) and 0.966 (wild-type alleles). In this small subset of the Mexican dog population, we found a higher prevalence of the nt230 (del4) MDR1/ABCB1 gene mutation than reported in other countries.
Assuntos
Genótipo , Alelos , Animais , Cães , Frequência do Gene , México/epidemiologia , MutaçãoRESUMO
Objective: Schizophrenia is a complex psychiatric disorder, characterized by disturbed patterns of thought and affecting 0.3-2.0% of the world population. Previously, the multidrug resistance 1 (MDR1) gene has been associated with schizophrenia in treatment response studies in psychotic patients. The aim of this study was to determine the association between MDR1 gene polymorphisms and clinical characteristics in patients with schizophrenia. Methods: Positive and negative symptoms of schizophrenia were assessed with the Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS) in 158 Mexican patients with schizophrenia. Analyses of MDR1 gene polymorphisms were performed using TaqMan technology. A multivariate ANOVA was performed with MDR1 polymorphisms and gender as independent variables. Results: Males with the G/G genotype of MDR1 rs2032582 presented significantly higher levels of delusions (p = 0.02). When comparing female vs. male groups, the difference was statistically significant (p = 0.0003). Analyses of the MDR1 gene rs1045642 variant showed no significant differences. Conclusion: Our findings suggest that male carriers of the G allele of variant rs2032582 exhibit greater severity of delusions; however, these results should be taken as preliminary, and replication studies in other populations of different ethnic origins are required to confirm these findings. .
Assuntos
Adolescente , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Estudos de Associação Genética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Polimorfismo de Nucleotídeo Único/genética , Esquizofrenia/genética , Análise de Variância , Frequência do Gene , Genótipo , México , Reação em Cadeia da Polimerase , Índice de Gravidade de Doença , Fatores SexuaisRESUMO
Overexpression of cytokine-induced apoptosis inhibitor 1 (CIAPIN1) contributes to multidrug resistance (MDR) in breast cancer. This study aimed to evaluate the potential of CIAPIN1 gene silencing by RNA interference (RNAi) as a treatment for drug-resistant breast cancer and to investigate the effect of CIAPIN1 on the drug resistance of breast cancer in vivo. We used lentivirus-vector-based RNAi to knock down CIAPIN1 in nude mice bearing MDR breast cancer tumors and found that lentivirus-vector-mediated silencing of CIAPIN1 could efficiently and significantly inhibit tumor growth when combined with chemotherapy in vivo. Furthermore, Western blot analysis showed that both CIAPIN1 and P-glycoprotein expression were efficiently downregulated, and P53 was upregulated, after RNAi. Therefore, we concluded that lentivirus-vector-mediated RNAi targeting of CIAPIN1 is a potential approach to reverse MDR of breast cancer. In addition, CIAPIN1 may participate in MDR of breast cancer by regulating P-glycoprotein and P53 expression.
Assuntos
Animais , Feminino , Humanos , Antibióticos Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Doxorrubicina/uso terapêutico , Resistencia a Medicamentos Antineoplásicos/genética , Inativação Gênica , Peptídeos e Proteínas de Sinalização Intracelular/genética , Western Blotting , Neoplasias da Mama/genética , Carcinoma/tratamento farmacológico , Carcinoma/genética , Modelos Animais de Doenças , Genes MDR , Vetores Genéticos/genética , Inibidores do Crescimento/genética , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Lentivirus/genética , Camundongos Endogâmicos BALB C , Camundongos Nus , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/efeitos dos fármacos , Interferência de RNA , RNA Interferente Pequeno/genética , /efeitos dos fármacosRESUMO
Aldosterone increases plasma volume and may be involved with resistant hypertension. P-glycoprotein is a transporter involved in the distribution and disposition of aldosterone, and is encoded by the MDR-1 gene. MDR-1 has functional polymorphisms that may affect P-glycoprotein expression. We hypothesized that the C(3435)T polymorphism in MDR-1 could be associated with resistant hypertension and with changes in hypertension-related parameters. We studied 105 healthy volunteers, 137 hypertensive patients responsive to treatment, and 83 resistant hypertensive patients. While we found no association of C(3435)T genotypes with resistance to treatment (p = 0.31), C allele was associated with hypertension (p = 0.03). Furthermore, the CC genotype was associated with higher systolic blood pressure (p < 0.01 for both daytime and nighttime, respectively) and diastolic blood pressure (p < 0.01 for both daytime and nighttime, respectively). This effect was probably independent of aldosterone, as we found no differences in aldosterone plasma levels, nor in pulse wave velocity (PVW) between the genotypes groups (p = 0.77 and p = 0.48, respectively). Our results show an association of C(3435)T with hypertension and with blood pressure levels in resistant hypertensive subjects.
Assuntos
Aldosterona/metabolismo , Pressão Sanguínea/genética , Hipertensão/tratamento farmacológico , Hipertensão/genética , Subfamília B de Transportador de Cassetes de Ligação de ATP/genética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Adulto , Idoso , Ritmo Circadiano , Resistência a Medicamentos , Feminino , Genótipo , Humanos , Hidrocortisona/sangue , Masculino , Pessoa de Meia-Idade , Polimorfismo Genético , Análise de Onda de Pulso , Renina/sangue , Rigidez VascularRESUMO
BACKGROUND AND AIM: The multi-drug resistant-1 (MDR-1) gene is located on human chromosome 7 and encodes a glycosylated membrane protein that is a member of the ATP-binding cassette transporters superfamily. The aim of the study was to reveal the role of the C3435T MDR-1 gene polymorphism in chronic obstructive pulmonary disease. METHOD: DNA samples from 41 patients with chronic obstructive pulmonary disease and 50 healthy control participants were used to compare MDR-1 gene profiles. Genotyping assays were performed using the StripAssay technique that is based on reverse-hybridization. RESULTS: The T allele polymorphism in the MDR-1 gene located at position 3435 in exon 26 was shown to correlate with chronic obstructive pulmonary disease. CONCLUSION: These preliminary results suggest that the T allele polymorphism of the MDR-1 gene is associated with chronic obstructive pulmonary disease.
Assuntos
Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resistência a Múltiplos Medicamentos/genética , Genes MDR/genética , Polimorfismo Genético/genética , Doença Pulmonar Obstrutiva Crônica/genética , Alelos , Estudos de Casos e Controles , Frequência do Gene/genética , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genéticaRESUMO
(MDR1) gene expressed in tumor cells and also in several normal tissues, such as intestine, liver, kidney, blood-brain barrier, spinal cord, and placenta. P-gp has been identified in mice, rat, bovine, monkey, rodents, and human beings and has been receiving a particular clinical relevance because this protein expression limits brain access and intestinal absorption of many drugs. This protein plays a role as a protective barrier against a wide variety of substrates, avoiding drug entry into the central nervous system. P-glycoprotein also interferes with drug bioavailability and disposition, including absorption, distribution, metabolization, and excretion, influencing pharmacokinetic and pharmacodynamic of drugs. Modulation of P-gp may help the efficacy of treatment of several diseases and can explain some adverse central nervous system effects induced by drugs after intravenous administration and the poor response of oral administration in patients. Alteration in P-gp expression or function has been associated with several diseases susceptibility in humans and animals. Furthermore, additional studies relating MDR1 and P-gp expression has an important clinical implication also in terms of treatment efficacy.
P-glicoproteína (P-gp) é um transportador de membrana ligado ao gene de resistência múltipla (MDR1), expressado em células tumorais e também em tecidos normais como intestino, fígado, rins, membranas hematoencefálica, hemo-placentária e medula espinhal. A P-gp já foi identificada em camundongos, ratos, bovinos, macacos, roedores e seres humanos e tem ganhado relevância clínica particular em função de sua expressão limitar o acesso de drogas ao cérebro e interferir com a absorção intestinal quando administradas pela via oral. Esta proteína participa da função protetora do organismo contra uma grande variedade de substratos, evitando a entrada de drogas no sistema nervoso central. A P-gp interfere também com a biodisponibilidade dos fármacos, incluindo absorção, distribuição, metabolização e excreção, influenciando assim, a farmacocinética e dinâmica dos mesmos. Desta maneira, a modulação da P-gp pode explicar alguns efeitos adversos no sistema nervoso central, induzidos por alguns fármacos após administração intravenosa, e a pobre resposta após administração oral em pacientes. A alteração na expressão ou função da P-glicoproteína tem sido associada a uma maior susceptibilidade a diversas doenças em humanos e animais. Estudos adicionais relacionados à expressão e à função da P-gp espécie-específica têm implicação clínica importante em termos de eficiência de tratamento.
RESUMO
(MDR1) gene expressed in tumor cells and also in several normal tissues, such as intestine, liver, kidney, blood-brain barrier, spinal cord, and placenta. P-gp has been identified in mice, rat, bovine, monkey, rodents, and human beings and has been receiving a particular clinical relevance because this protein expression limits brain access and intestinal absorption of many drugs. This protein plays a role as a protective barrier against a wide variety of substrates, avoiding drug entry into the central nervous system. P-glycoprotein also interferes with drug bioavailability and disposition, including absorption, distribution, metabolization, and excretion, influencing pharmacokinetic and pharmacodynamic of drugs. Modulation of P-gp may help the efficacy of treatment of several diseases and can explain some adverse central nervous system effects induced by drugs after intravenous administration and the poor response of oral administration in patients. Alteration in P-gp expression or function has been associated with several diseases susceptibility in humans and animals. Furthermore, additional studies relating MDR1 and P-gp expression has an important clinical implication also in terms of treatment efficacy.
P-glicoproteína (P-gp) é um transportador de membrana ligado ao gene de resistência múltipla (MDR1), expressado em células tumorais e também em tecidos normais como intestino, fígado, rins, membranas hematoencefálica, hemo-placentária e medula espinhal. A P-gp já foi identificada em camundongos, ratos, bovinos, macacos, roedores e seres humanos e tem ganhado relevância clínica particular em função de sua expressão limitar o acesso de drogas ao cérebro e interferir com a absorção intestinal quando administradas pela via oral. Esta proteína participa da função protetora do organismo contra uma grande variedade de substratos, evitando a entrada de drogas no sistema nervoso central. A P-gp interfere também com a biodisponibilidade dos fármacos, incluindo absorção, distribuição, metabolização e excreção, influenciando assim, a farmacocinética e dinâmica dos mesmos. Desta maneira, a modulação da P-gp pode explicar alguns efeitos adversos no sistema nervoso central, induzidos por alguns fármacos após administração intravenosa, e a pobre resposta após administração oral em pacientes. A alteração na expressão ou função da P-glicoproteína tem sido associada a uma maior susceptibilidade a diversas doenças em humanos e animais. Estudos adicionais relacionados à expressão e à função da P-gp espécie-específica têm implicação clínica importante em termos de eficiência de tratamento.